GERN
NASDAQ · Biotechnology
Geron Corp
$1.28
-0.01 (-0.78%)
Open$1.30
Previous Close$1.29
Day High$1.30
Day Low$1.24
52W High$2.01
52W Low$1.04
Volume—
Avg Volume14.73M
Market Cap973.35M
P/E Ratio—
EPS$-0.10
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+1,385.2% upside
Current
$1.28
$1.28
Target
$19.01
$19.01
$12.94
$19.01 avg
$24.33
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 209.73M | 153.95M | 141.15M |
| Net Income | -95,281,575 | -36,660,557 | -32,364,939 |
| Profit Margin | -45.4% | -23.8% | -22.9% |
| EBITDA | -77,715,698 | -44,322,691 | -40,350,825 |
| Free Cash Flow | — | -25,979,960 | -28,291,864 |
| Rev Growth | +574.2% | +15.1% | +6.9% |
| Debt/Equity | 1.10 | 0.42 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |